A Phase II Open-Label Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ATL1103 300mg in Adult Patients with Acromegaly.

Trial Profile

A Phase II Open-Label Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ATL1103 300mg in Adult Patients with Acromegaly.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Atesidorsen (Primary)
  • Indications Acromegaly
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Antisense Therapeutics
  • Most Recent Events

    • 04 Apr 2017 Status changed from recruiting to completed.
    • 11 Mar 2016 According to Antisense media release, full dosing is expected to be completed in June 2016.
    • 09 Sep 2015 According to Antisense Therapeutics, dosing of patients will be completed by end of this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top